CAR-T for solid tumors: the approved gastric cancer use and trial options

What changed for solid-tumor CAR-T

The Chinese approval of satricabtagene autoleucel, commonly called satri-cel or CT041, creates a defined treatment option for a selected group of patients with advanced gastric or gastroesophageal junction adenocarcinoma. It is a Claudin18.2-directed autologous CAR-T product.

The practical question is whether your pathology and treatment history fit that indication. Bring the diagnosis, CLDN18.2 result, HER2 result and earlier treatment records to the review. The receiving team can then explain whether an approved-product assessment is relevant and what additional information is needed.

Sources and references: [1] [2]

A positive target needs the right test and disease context

CAR-T cells recognize a particular protein on the surface of cells. For satri-cel, the relevant target is CLDN18.2. Ask which tissue sample was tested, which assay was used and whether the report contains the detail required by the treating center. A pathology review may be needed if the result is incomplete.

The rest of the indication remains important too, including HER2-negative status, the cancer location and previous lines of treatment. A CLDN18.2-positive result in pancreatic cancer, for example, leads to a different discussion from the approved gastric cancer setting.

Sources and references: [1] [2]

Why results differ across solid tumors

Solid cancers can vary greatly in the proteins they express, even between cells within the same tumor. CAR-T cells also have to reach the cancer and remain active in its surrounding environment. These factors help explain why a successful target in one setting needs separate investigation in another.

When considering a study, ask how the target was confirmed and which type of cancer was treated in the reported results. Evidence from a small group can help identify a research opportunity, while the decision for you depends on the actual protocol and available alternatives.

Sources and references: [3] [4]

Other uses need a named research pathway

Research is continuing in cancers including pancreatic tumors and brain tumors, and in earlier treatment settings. CARsgen's June 2026 update describes pancreatic adjuvant and earlier gastric cancer studies. These are distinct from the approved later-line gastric indication.

Ask for the study identifier, location, recruiting status and entry criteria. The team should explain what treatment is being tested, how often visits are required and what options remain if screening is unsuccessful. Confirm the current study arrangements with the site before planning a journey around enrollment.

Sources and references: [2] [3] [4]

Compare CAR-T with the care available now

A solid-tumor review should include the treatments relevant to the cancer's stage and biomarkers, as well as CAR-T. Ask what the team expects from each option, how quickly it can start and what the next step would be if it does not control the disease.

For an approved satri-cel assessment, ask for the evidence in patients with a similar treatment history and the outcomes the team uses to judge benefit. For a trial, ask about the study's phase and purpose. This helps you understand whether the immediate task is choosing an available treatment or considering research participation.

Sources and references: [5] [2]

Plan for collection, preparation and monitoring

Autologous CAR-T involves collecting cells, modifying and expanding them, and returning the product after the planned preparatory regimen. The schedule depends on the product and center. Ask whether treatment is needed to control the cancer while the cells are being prepared and how your condition will be reassessed before infusion.

CAR-T can cause immune reactions such as CRS, as well as other toxicities related to the product and preparatory medicines. Ask the team to explain the specific safety experience for the proposed solid-tumor treatment, including infection, blood-count support and any risks linked to the tumor's location.

Sources and references: [3] [2]

Turn a treatment claim into questions you can use

If you have seen a striking CAR-T result online, save the product name and the source. Ask whether it concerns the same cancer, target and treatment line as yours. Find out how many people received treatment, how response was measured and how long they were followed.

The center should also explain the practical route: approved care or a registered study, required tests, expected visits and the cost categories to clarify. A written plan makes it easier to compare options with your current oncologist and decide whether the proposed trip addresses a realistic treatment opportunity.

Sources and references: [5] [4]

Start with an oncology and pathology review in Shanghai

For a solid tumor, the starting service is an oncology review matched to your cancer, with pathology and molecular assessment where needed. Shanghai hospital resources can then be considered according to the proposed treatment or study and the receiving team's requirements.

EastMedGo can help organize the pathology, biomarker results, scans and treatment timeline for that review. Contact us with the exact diagnosis and any product or trial you want assessed. We can coordinate appointment requests and clarify document and travel requirements after the appropriate clinical pathway has been identified.

Common questions